Multi-level specific targeting of cancer cells

Patent metadata

Field	Value
Publication number	US-10519210-B2
Application number	US-201916262195-A
Country	US
Kind code	B2
Filing date	Jan 30, 2019
Priority date	Apr 16, 2010
Publication date	Dec 31, 2019
Grant date	Dec 31, 2019

Abstract

A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.

First claim

That which is claimed is:

1. A method of delivering at least one effector molecule to a subcellular compartment of a cell of interest, comprising:
contacting to the cell of interest a fusion protein or covalent conjugate having a formula, from N terminus to C terminus, selected from the group consisting of:
A-B-C-D-E,
E-D-C-B-A,
A-B-D-C-E; and
E-C-D-B-A,
wherein:
A is IL-13, a mutant of IL-13, or an IL-13Rα2 binding fragment thereof;
B is a cytosol localization element, wherein said cytosol localization element is a Pseudomonas exotoxin or diphtheria toxin translocation domain;
C is a subcellular compartment localization signal element, wherein said subcellular compartment localization signal element is a nuclear localization element, a lysosomal localization element, or a mitochondrial localization element;
D is a first effector molecule, wherein said first effector molecule comprises a therapeutic agent or a detectable group; and
E is a second effector molecule that is present or absent and when present comprises a therapeutic agent or a detectable group,
wherein said contacting is carried out under conditions in which said fusion protein or covalent conjugate is internalized by the cell of interest and said effector molecule is delivered to said subcellular compartment.

2. The method of claim 1 , wherein A is IL-13.

3. The method of claim 1 , wherein A is a mutant of IL-13.

4. The method of claim 3 , wherein said mutant of IL-13 is IL-13.E13K.

5. The method of claim 1 , wherein said cytosol localization element is a Pseudomonas exotoxin translocation domain.

6. The method of claim 5 , wherein said cytosol localization element is a Pseudomonas exotoxin A D2 segment.

7. The method of claim 1 , wherein said subcellular compartment localization signal element is a nuclear localization element.

8. The method of claim 7 , wherein said nuclear localization element is an SV40 T antigen nuclear localization signal.

9. The method of claim 1 , wherein said subcellular compartment localization signal element is a lysosomal localization element.

10. The method of claim 1 , wherein said subcellular compartment localization signal element is mitochondrial localization element.

11. The method of claim 1 , wherein said at least one effector molecule comprises a detectable group.

12. The method of claim 1 , wherein said at least one effector molecule comprises a toxin.

13. The method of claim 12 , wherein the toxin is a diphtheria toxin or a Pseudomonas exotoxin.

14. The method of claim 1 , wherein said at least one effector molecule comprises an amphipathic antimicrobial peptide.

15. The method of claim 14 , wherein the amphipathic antimicrobial peptide comprises a sequence selected from the group consisting of: (KLAKLAK) 2 (SEQ ID NO: 60); (KLAKKLA) 2 (SEQ ID NO: 61); (KAAKKAA) 2 (SEQ ID NO: 62) and (KLGKKLG) 2 (SEQ ID NO: 63).

16. The method of claim 1 , wherein said at least one effector molecule comprises a chemotherapeutic agent.

17. The method of claim 16 , wherein the chemotherapeutic agent is selected from the group consisting of: methotrexate, daunomycin, mitomycin C, cisplatin, vincristine, epirubicin, fluorouracil, verapamil, cyclophosphamide, cytosine arabinoside, aminopterin, bleomycin, mitomycin C, democolcine, etoposide, mithramycin, chlorambucil, melphalan, daunorubicin, doxorubicin, tamosifen, paclitaxel, vincristin, vinblastine, camptothecin, actinomycin D, and cytarabine.

18. The method of claim 16 , wherein the chemotherapeutic agent is an anthracycline.

19. The method of claim 18 , wherein the chemotherapeutic agent is doxorubicin or daunorubicin.

20. The method of claim 1 , wherein said fusion protein or covalent conjugate has the formula: A-B-C-D-E or E-D-C-B-A.

21. The method of claim 1 , wherein said second effector molecule is present.

Assignees

• Univ Wake Forest Health Sciences

Inventors

• Debinski Waldemar
• Pandya Hetal
• Gibo Denise

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/5091

  for testing the pathological state of an organism · CPC title

• C07K14/21

  from Pseudomonadaceae (F) · CPC title

• G01N33/532

  Production of labelled immunochemicals · CPC title

• C07K14/34 Primary

  from Corynebacterium (G) · CPC title